DAMORA THERAPEUTICS, INC. Shareholders' Equity
DAMORA THERAPEUTICS, INC. (DMRA) had Shareholders' Equity of $516.06 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $516.06M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $511.60M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $240.38M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $8.01M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $516.06M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $511.60M 10-Q · filed 2026-08-10 |
| 2025-12-31 | $240.38M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $8.01M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $10.95M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $13.71M 10-Q · filed 2026-08-10 |
| 2024-12-31 | $15.83M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $20.93M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $23.59M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $28.16M 10-Q · filed 2025-08-05 |
| 2023-12-31 | $32.33M 10-K · filed 2026-03-19 |
| 2023-09-30 | $37.38M 10-Q · filed 2024-11-01 |
| 2023-06-30 | $43.70M 10-Q · filed 2024-11-01 |
| 2023-03-31 | $50.33M 10-Q · filed 2024-08-12 |
| 2022-12-31 | $61.75M 10-K · filed 2025-03-19 |
| 2022-09-30 | $72.73M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $85.06M 10-Q · filed 2023-11-06 |
| 2022-03-31 | $101.31M 10-Q · filed 2023-07-31 |
| 2021-12-31 | $117.22M 10-K · filed 2024-03-08 |
| 2021-09-30 | $129.62M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $141.43M 10-Q · filed 2022-11-08 |
| 2021-03-31 | $152.57M 10-Q · filed 2022-07-29 |
| 2020-12-31 | $165.49M 10-K · filed 2023-03-09 |
| 2020-09-30 | -$91.74M 10-Q · filed 2021-11-04 |
| 2020-06-30 | -$82.55M 10-Q · filed 2021-11-04 |
| 2020-03-31 | -$77.03M 10-Q · filed 2021-08-05 |
| 2019-12-31 | -$71.15M 10-K · filed 2022-02-17 |
| 2019-09-30 | -$48.06M 10-Q · filed 2020-12-11 |
| 2019-06-30 | -$41.89M 10-Q · filed 2020-12-11 |
| 2018-12-31 | -$33.84M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |